Literature DB >> 30302207

Identifying targetable genetic features in primary CNS lymphoma.

Agnieszka Korfel1,1, Uwe Schlegel2,2.   

Abstract

Entities:  

Keywords:  blood–brain barrier; target therapy; toxicity

Year:  2017        PMID： 30302207      PMCID： PMC6171987          DOI： 10.2217/ijh-2016-0012

Source DB:  PubMed          Journal:  Int J Hematol Oncol        ISSN： 2045-1393


× No keyword cloud information.
  19 in total

1.  Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.

Authors:  Sophie Bernard; Lauriane Goldwirt; Sandy Amorim; Pauline Brice; Josette Brière; Eric de Kerviler; Samia Mourah; Hélène Sauvageon; Catherine Thieblemont
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

Review 2.  Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.

Authors:  Martina Deckert; Manuel Montesinos-Rongen; Anna Brunn; Reiner Siebert
Journal:  Acta Neuropathol       Date:  2013-11-16       Impact factor: 17.088

3.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Authors:  Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

4.  Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.

Authors:  Patrick Roth; Peter Martus; Philipp Kiewe; Robert Möhle; Hermann Klasen; Michael Rauch; Alexander Röth; Stephan Kaun; Eckhard Thiel; Agnieszka Korfel; Michael Weller
Journal:  Neurology       Date:  2012-08-15       Impact factor: 9.910

5.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Authors:  Wyndham H Wilson; Ryan M Young; Roland Schmitz; Yandan Yang; Stefania Pittaluga; George Wright; Chih-Jian Lih; P Mickey Williams; Arthur L Shaffer; John Gerecitano; Sven de Vos; Andre Goy; Vaishalee P Kenkre; Paul M Barr; Kristie A Blum; Andrei Shustov; Ranjana Advani; Nathan H Fowler; Julie M Vose; Rebecca L Elstrom; Thomas M Habermann; Jacqueline C Barrientos; Jesse McGreivy; Maria Fardis; Betty Y Chang; Fong Clow; Brian Munneke; Davina Moussa; Darrin M Beaupre; Louis M Staudt
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

6.  Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Authors:  Sophie Langner-Lemercier; Caroline Houillier; Carole Soussain; Hervé Ghesquières; Olivier Chinot; Luc Taillandier; Pierre Soubeyran; Thierry Lamy; Franck Morschhauser; Alexandra Benouaich-Amiel; Guido Ahle; Marie-Pierre Moles-Moreau; Cécile Moluçon-Chabrot; Pascal Bourquard; Ghandi Damaj; Fabrice Jardin; Delphine Larrieu; Emmanuel Gyan; Remy Gressin; Arnaud Jaccard; Sylvain Choquet; Annie Brion; Olivier Casasnovas; Philippe Colin; Oumedaly Reman; Adrian Tempescul; Jean-Pierre Marolleau; Michel Fabbro; Florian Naudet; Khê Hoang-Xuan; Roch Houot
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

Review 7.  Diagnosis and treatment of primary CNS lymphoma.

Authors:  Agnieszka Korfel; Uwe Schlegel
Journal:  Nat Rev Neurol       Date:  2013-05-14       Impact factor: 42.937

8.  Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.

Authors:  Alberto Gonzalez-Aguilar; Ahmed Idbaih; Blandine Boisselier; Naïma Habbita; Marta Rossetto; Alice Laurenge; Aurélie Bruno; Anne Jouvet; Marc Polivka; Clovis Adam; Dominique Figarella-Branger; Catherine Miquel; Anne Vital; Hervé Ghesquières; Rémy Gressin; Vincent Delwail; Luc Taillandier; Olivier Chinot; Pierre Soubeyran; Emmanuel Gyan; Sylvain Choquet; Caroline Houillier; Carole Soussain; Marie-Laure Tanguy; Yannick Marie; Karima Mokhtari; Khê Hoang-Xuan
Journal:  Clin Cancer Res       Date:  2012-07-26       Impact factor: 12.531

9.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors:  James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

10.  Mutational analysis of primary central nervous system lymphoma.

Authors:  Aurélie Bruno; Blandine Boisselier; Karim Labreche; Yannick Marie; Marc Polivka; Anne Jouvet; Clovis Adam; Dominique Figarella-Branger; Catherine Miquel; Sandrine Eimer; Caroline Houillier; Carole Soussain; Karima Mokhtari; Romain Daveau; Khê Hoang-Xuan
Journal:  Oncotarget       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.